RNAC (Cartesian Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Cartesian Therapeutics, Inc. Common Stock (RNAC) is a publicly traded Healthcare sector company. As of May 21, 2026, RNAC trades at $6.50 with a market cap of $202.44M and a P/E ratio of -1.27. RNAC moved +7.31% today. Year to date, RNAC is -5.64%; over the trailing twelve months it is -36.27%. Its 52-week range spans $5.60 to $26.50. Analyst consensus is strong buy with an average price target of $32.20. Rallies surfaces RNAC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns RNAC stock?

Hedge funds tracked by Rallies that own RNAC include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cartesian Therapeutics, Inc. Common Stock.

RNAC Key Metrics

Key financial metrics for RNAC
MetricValue
Price$6.50
Market Cap$202.44M
P/E Ratio-1.27
EPS$-5.02
Dividend Yield0.00%
52-Week High$26.50
52-Week Low$5.60
Volume900
Avg Volume0
Revenue (TTM)$2.80M
Net Income$-130.30M
Gross Margin0.00%

Top Hedge Funds Holding RNAC

  • Citadel Advisors holds 315.00K shares of RNAC, changed +5025.28% as of Dec 31, 2024.
  • Renaissance Technologies holds 13.80K shares of RNAC, changed -19.07% as of Dec 31, 2024.
  • Two Sigma holds 11.81K shares of RNAC, changed -8.51% as of Dec 31, 2024.

Latest RNAC News

Recent RNAC Insider Trades

  • Brunn Carsten sold 23.77K (~$162.08K) on Jan 6, 2026.
  • Miljkovic Milos sold 3.57K (~$24.37K) on Jan 6, 2026.
  • Davis Blaine sold 10.59K (~$72.23K) on Jan 6, 2026.

RNAC Analyst Consensus

6 analysts cover RNAC: 0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.20.

Common questions about RNAC

Who owns RNAC stock?
Hedge funds tracked by Rallies that own RNAC include Citadel Advisors, Renaissance Technologies, and Two Sigma. The latest tracked quarter is Dec 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cartesian Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for RNAC?
Yes. Rallies tracks hedge fund and 13F ownership data for RNAC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is RNAC research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RNAC. It does not provide personalized investment advice.
RNAC

RNAC